Allena Pharmaceuticals Inc is a US-based late-stage clinical biopharmaceutical company. It is developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company focuses on metabolic disorders which result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and lead to chronic kidney disease (CKD), and end-stage renal disease. Its key product candidates are ALLN-177 which is an oral enzyme therapeutic developing for the treatment of hyperoxaluria, and ALLN-346 is being developed for patients with hyperuricemia and moderate to severe CKD.